New York State Teachers Retirement System trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 120,842 shares of the biopharmaceutical company’s stock after selling 461 shares during the period. New York State Teachers Retirement System owned approximately 0.12% of Regeneron Pharmaceuticals worth $54,031,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Oppenheimer & Co. Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 20.6% during the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after purchasing an additional 1,199 shares during the last quarter. Dupont Capital Management Corp purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $220,000. Shell Asset Management Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 24.1% during the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares during the last quarter. Blair William & Co. IL lifted its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares during the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.

In related news, CFO Robert E. Landry sold 189 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders have sold 89,468 shares of company stock valued at $42,312,448 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Several research firms have recently issued reports on REGN. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday. Guggenheim reiterated a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Barclays PLC lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $450.00 to $395.00 in a report on Friday, October 20th. Canaccord Genuity reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Finally, Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Four research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $488.57.

ILLEGAL ACTIVITY WARNING: “New York State Teachers Retirement System Sells 461 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/11/02/new-york-state-teachers-retirement-system-sells-461-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% compared to the same quarter last year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.